-+ 0.00%
-+ 0.00%
-+ 0.00%

Vir to present Phase 2 SOLSTICE Week 96 hepatitis delta data at EASL 2026

PUBT·05/18/2026 20:06:18
Listen to the news
Vir to present Phase 2 SOLSTICE Week 96 hepatitis delta data at EASL 2026
  • Vir Biotechnology flagged upcoming presentations at EASL Congress 2026 in Barcelona, with complete Week 96 results from its Phase 2 SOLSTICE trial in chronic hepatitis delta scheduled for May 29.
  • The data set will cover efficacy and safety for tobevibart used alone or in combination with elebsiran, aimed at supporting the program’s longer-term benefit-risk profile.
  • A separate Week 48 subgroup analysis is set for poster sessions on May 27 and May 29, examining how body weight factors relate to liver enzyme normalization once viral control is achieved on the combination regimen.
  • The Week 96 readout was selected for “Best of EASL 2026,” signaling elevated visibility for investors tracking late-stage positioning in hepatitis delta.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605181605BIZWIRE_USPR_____20260518_BW708069) on May 18, 2026, and is solely responsible for the information contained therein.